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Abstract
The role of APOBEC3 (A3) protein family members in inhibiting retrovirus infection and mobile element retrotransposition is
well established. However, the evolutionary effects these restriction factors may have had on active retroviruses such as HIV-
1 are less well understood. An HIV-1 variant that has been highly G-to-A mutated is unlikely to be transmitted due to
accumulation of deleterious mutations. However, G-to-A mutated hA3G target sequences within which the mutations are
the least deleterious are more likely to survive selection pressure. Thus, among hA3G targets in HIV-1, the ratio of
nonsynonymous to synonymous changes will increase with virus generations, leaving a footprint of past activity. To study
such footprints in HIV-1 evolution, we developed an in silico model based on calculated hA3G target probabilities derived
from G-to-A mutation sequence contexts in the literature. We simulated G-to-A changes iteratively in independent
sequential HIV-1 infections until a stop codon was introduced into any gene. In addition to our simulation results, we
observed higher ratios of nonsynonymous to synonymous mutation at hA3G targets in extant HIV-1 genomes than in their
putative ancestral genomes, compared to random controls, implying that moderate levels of A3G-mediated G-to-A
mutation have been a factor in HIV-1 evolution. Results from in vitro passaging experiments of HIV-1 modified to be highly
susceptible to hA3G mutagenesis verified our simulation accuracy. We also used our simulation to examine the possible role
of A3G-induced mutations in the origin of drug resistance. We found that hA3G activity could have been responsible for
only a small increase in mutations at known drug resistance sites and propose that concerns for increased resistance to
other antiviral drugs should not prevent Vif from being considered a suitable target for development of new drugs.
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Introduction
The human and mouse APOBEC3 (A3) protein family
members, hA3F and G and mA3, respectively, are well-studied
host factors that restrict retrovirus replication. [1–3]. These
components of the innate cellular defense system inhibit retroviral
propagation by inducing deamination of C-to-U residues in the
negative strand of retroviral DNA during reverse transcription [4],
resulting in a mutated provirus with biased G-to-A changes on the
plus strand [5–8]. Due to the specificity of A3 for single-stranded
DNA, the frequency of induced mutations forms an increasing
gradient in the genome from the primer binding site (PBS) to the
polypurine tract (PPT) [9]. In the case of HIV-1, whose genome
contains a central PPT (cPPT), this effect results in dual gradients
of G-to-A mutations from the PBS to the cPPT and the cPPT to
the PPT [10]. A role of A3-mediated defense in more distant
retroviral evolution became apparent when we recently showed
that mA3 likely contributed to inactivation of the infectivity of
some types of endogenous MLV at the time of their integration
into the host germline around a million years ago [11]. Taken
together, these observation show that A3 was active as an antiviral
factor in the distant evolutionary past, and that it is so today.
However, the effects these APOBEC3 restriction factors have had
on the evolution of actively replicating retroviruses such as HIV-1
are less clear.
The present study was undertaken to look for a signal of past
A3-induced G-to-A changes in the sequence of modern day HIV-1
genomes. We hypothesized that the observed variation in G:A
ratios in different viruses and in their sensitivities to A3 [5,12,13] is
partly an effect of earlier A3-induced mutation and selection
pressure on the virus genomes. Highly G-to-A mutated sequences
are unlikely to be transmitted due to deleterious mutations.
However, less efficient A3 activity, and thus fewer G-to-A
mutations, could allow virus transmission, although with reduced
efficiency. In this scenario, mutated A3 target sequences within
which G-to-A mutations are the least deleterious are more likely to
survive purifying selection pressure. This model predicts that as
mutations accumulate with time, the ratio of nonsynonymous (NS)
to synonymous (S) sites in probable A3 target sequences will
increase with increasing virus generations more rapidly than at
sites that are not A3 targets.
To study the potential of human APOBEC3G (hA3G) to affect
HIV-1 evolution, we developed an in silico model that takes into
account the observed mutation gradient and the probabilities of
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contexts of mutation sites (hereafter referred to as ‘‘contexts’’)
found in the literature [9,14]. After adjustment for location in the
provirus in our simulations, we found that the frequency of G-to-A
mutations introduced into HIV-1 could be partly explained by the
virus’s genetic profile as well as its distribution of probable target
sequence contexts. Our simulation approach is supported by
independent experimental results obtained by passaging HIV-1
under conditions that permit a high level of A3G-induced
mutation. Further analyses showed that the ratio of NS to S-
mutations at hA3G target sites has increased during HIV-1
evolution compared to random controls, implying an evolution
where A3 sites have had higher mutation rates than non-A3 sites
and therefore been subjected to greater influence from purifying
selection. We also analyzed the potential of low-level hA3G-
mediated G-to-A mutations to give rise to naturally occurring drug
resistance mutations.
Materials and Methods
Human APOBEC3G mutation site contexts and
probabilities
To calculate the likelihood of hA3G-mediated G-to-A mutation
at different sites in HIV-1, we analyzed mutation site contexts
surrounding 1324 observed G-to-A mutations attributed to hA3G
from the literature [9,14]. Given the variability in these data and
to minimize false predictions, we used our previous experience
with mutation site context analyses [11] and included as many
significant sites as possible (Figure S1). Thus, we collected
sequences up to 3 bases 59 and 5 bases 39 of the G-to-A mutations.
Using nucleotide frequencies at each offset position from the
mutation target G-nucleotide, we constructed a position-specific
scoring matrix (PSSM, Figure S1) using odds ratios (i.e., observed
relative to expected nucleotide frequencies) and similar to the one
derived for our previous study on endogenous nonecotropic MLVs
[11]. Due to limited representation of observed non-A3G
mediated G-to-A mutation sites in the literature, we included an
artificial nucleotide frequency background to compensate for
sampling artifacts using a previously described pseudo count
method (Figure S1) [15]. Using automated PERL scripts we
simulated a collection of 10
6 random mutation site contexts based
on nucleotide frequencies observed in HIV-1. These data were
used to derive a score distribution and a cumulative frequency
distribution for probability calculation of context scores. Scores for
the previously described G-to-A contexts were calculated and
compared to the newly calculated score and cumulative frequency
distributions. An analysis of G-to-A mutation site contexts
collected from endogenous MLVs [11] supported this putative
cutoff for likely A3 targets (data not shown). In addition to our
simulations using all hA3G targets, we also included separate
analyses using the 80% probability cutoff for introduction of G-to-
A mutations (see below).
Simulated retrovirus evolution from G-to-A mutations
Mutations were simulated in HIV-1 (AF033819) using auto-
mated PERL scripts as outlined in Figure 1. Briefly, a mutation
position was randomly selected using the previously observed dual
gradients of increasing likelihood for mutation in the PBS-cPPT
and cPPT-39PPT regions [9,10]. A score for the sequence context
surrounding each randomly selected G-nucleotide was compared
against cumulative frequency distributions of simulated random
viral hA3G target contexts, and used to test whether a G-to-A
mutation should be introduced at that site. If the context likelihood
exceeded a random number between 0 and 1 a G-to-A mutation
was introduced at that site. Failure to introduce a mutation
initiated a new attempt at another random position. Information
from successful mutations, including their location and whether
they were synonymous (S) or nonsynonymous (NS) (i.e. unchanged
and changed amino acid respectively) – was collected and followed
by another round of simulated G-to-A mutation. Simulations were
repeated until a stop codon was introduced into any gene or a
normal ATG initiation codon was altered, after which the HIV-1
sequence with accumulated G-to-A mutations was collected into a
database. In this way, we collected 4000 independent genomes
with accumulated G-to-A mutations. All simulation rounds were
performed using either contexts with probabilities over 80% or all
G-nucleotides independent of context.
Test of evolutionary G-to-A mutation footprints in HIV-1
To analyze the potential evolutionary footprints of hA3G-
mediated G-to-A mutations in HIV-1 we used automated PERL
scripts to test the ratios between the summarized probabilities of
nonsynonymous to synonymous G-nucleotide contexts. To look
for mutations that might have occurred during the evolutionary
history of the virus, the same analysis was performed for putative
ancestral G-nucleotide targets observed as A-nucleotides in the
virus. Ratios were compared using a x
2 test (1 degree of freedom)
for HIV-1 (AF033819) and HIVcon (group M consensus sequence
derived from subgroup gene alignment consensus sequences)
downloaded from www.hiv.lanl.gov.
Potential HIV-1 drug resistance from hA3G-mediated G-
to-A mutations
Locations of known HIV-1 protease inhibitor (PI), nucleoside
RT inhibitors (NRTI), non-nucleoside RT inhibitor (NNRTI),
integrase inhibitor (INI), and fusion inhibitor (FI) resistance
mutation sites were collected from the literature [16] and the
HIV drug resistance database (http://hivdb.stanford.edu). We
then analyzed all G-nucleotide contexts and used their calculated
probabilities in our in silico model to estimate the potential
likelihood for hA3G-mediated G-to-A mutations leading to drug
resistance.
Author Summary
The search for new drugs to battle HIV-1 infections is a
continuing struggle. APOBEC3G proteins have been shown
to deaminate C-residues in HIV-1 minus strand DNA during
its synthesis, resulting in G-to-A mutations in the RNA
genome. The HIV-1 Vif protein has evolved to counteract
APOBEC3G and thereby escape these frequently deleteri-
ous mutations, making Vif an attractive target for new
drugs. However, a partial block of Vif could result in an
increased although low-level HIV-1 G-to-A mutation rate.
Here we investigated APOBEC3G mutation footprints in
HIV-1 evolution and the potential risk for known drug
resistance from sublethal G-to-A mutations. Using com-
puter simulations, the accuracies of which were verified by
infection experiments, we detected evolutionary APO-
BEC3G mutation footprints in the HIV-1 genome. We
predict that the risk that APOBEC3G-induced G-to-A
mutations will cause drug resistance is very low. We
therefore propose that concerns for increased resistance to
other antiviral drugs should not prevent Vif from being
considered a suitable target for development of new
drugs.
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HIV-1
Highly mutated HIV-1 samples were obtained from a passaging
experiment. A detailed description of these studies [17] is available
upon request. In brief, the YRHHY.A5 mutation at amino acids
40 to 44, which renders HIV-1 Vif unable to efficiently bind to
hA3G but still be effective against hA3F [18], was inserted into the
replication-competent HIV-1 plasmid pNL4-3 (AF324493) using
overlapping PCR to generate pNL4-3-YRHHY.A5. For virus
production, 4610
6 293T cells were transfected with 20 mgo f
either pNL4-3 or pNL4-3-YRHHY.A5 and 1.2 mg pGL, which
expresses the green fluorescent protein from a cytomegalovirus
immediate early promoter (Invitrogen) to determine transfection
efficiency. The virus-containing supernatant was harvested 48-
hours after transfection, and assayed for RT activity. On day one
of infection, 1610
6 CEM cells were infected with 200 ml of virus
supernatant (1000 RT units of virus) for five hours. The volume of
medium was then increased to 5 ml. A 4 ml aliquot of cells and
virus-containing supernatant was removed at two day intervals
post infection (days 3, 5, 7 etc.), and stored at 270uC for
subsequent analysis. A 4 ml aliquot of fresh CEM-CM (complete
medium, RPMI+10% fetal calf serum+1% penicillin-streptomy-
cin, in which the CEM cells were maintained). was then added to
the remaining 2 ml cell and virus suspension and the sample
incubated for another 2 days.
PCR reactions using 2 ml of extracted DNA from the infected
cells, 1 ml High Fidelity Platinum Taq polymerase (Invitrogen) and
20 pmoles each of Vif F (59CAGGGAGATTCTAAAAG39) and
Vif R (59GGATAAACAGCAGTTGTTGC39) primers were
performed at 98 C for 2 minutes, followed by 30 cycles at 98 C
Figure 1. Simulation strategies and analyses. A mutation position was randomly selected along the provirus, considering dual likelihood
gradients, and analyzed for its surrounding context score and fitness to a hA3G target using simulated score and cumulative frequency distributions
(as shown in the graph; see Figure 2A). A random number between 0 and 1 was chosen. If the context likelihood at the chosen site exceeded that
value, a G-to-A mutation was introduced at that site. Failure to mutate initiated another attempt for a random mutation position. For a successful
mutation, its position and synonymous or nonsynonymous change in amino acid were recorded and the mutated sequence was subjected to
another round of mutation. This process was iterated until a stop codon was recorded in any ORF, at which point the sequence was collected into a
database and a new simulation was initiated. Four thousand independent simulations were performed for each run.
doi:10.1371/journal.ppat.1000367.g001
A3G, HIV-1 Evolution and Drug Resistance
PLoS Pathogens | www.plospathogens.org 3 April 2009 | Volume 5 | Issue 4 | e1000367for 30 seconds, 55 C for 30 seconds and 72 C for one minute.
Final PCR product extension was performed at 72 C for
10 minutes. The PCR product was then cloned into the TOPO
TA vector (Invitrogen) and the individual clones were sequenced
using the primer NL43 seq 4921F (59GAGATCCAGTTTG-
GAAAGGAC39).
Evaluation of the in silico model
Mutation site contexts from the in vitro experiments described
above were collected using automated PERL scripts as described
earlier [11]. Scores and likelihoods were calculated in our current
model. In these experiments, G-to-A mutations were considered
either natural RT errors or hA3G-mediated changes since the
YRHHY.A5 vif mutant is still capable of inhibiting hA3F [18].
To evaluate our in silico model, we simulated the number of
mutations we observed in vitro on the same vif region of pNL4-3
(AF324493; positions 5041–5770). We then isolated all contexts
surrounding simulated G-to-A mutations using our automated
PERL scripts and calculated scores and likelihoods for direct
comparison to the in vitro results.
Results
Simulated HIV-1 evolution due to G-to-A mutations
Using automated PERL scripts and previously identified hA3G-
induced mutations [9,14], we extracted sequence contexts
extending 3 bases upstream and 5 bases downstream of each
potential G-to-A mutation position in the HIV-1 genome and
constructed a Log position-specific scoring matrix (PSSM, Figure
S1). We next created a random set of 10
6 mutation site contexts
(Figure 2A, circles) based on the HIV-1 base composition and
plotted the histogram and cumulative frequencies of that
distribution (Figure 2A, diamonds). This analysis yielded an
approximately normal distribution with a mean score of 20.7 and
a standard deviation of 1.5 (black boxplot). To determine the
pattern of actual mutations, we then tested context scores of
previously observed G-to-A mutation sites [14] against this
distribution. The distribution of calculated probabilities of these
mutation ‘‘hotspots’’ [14] was significantly skewed relative to
random, with a mean of 2.3 and a standard deviation of 1.1
(Figure 2A; red boxplot), with 96% of mutations at sites with a
score of 80% or greater, suggesting that a score threshold of 80%
would capture the large majority of actual hA3G-mutation targets.
We also found support for an 80% cutoff when G-to-A mutation
site contexts collected from endogenous MLVs [11] were analyzed
in the same way using simulated score distributions.
To estimate the potential of hA3G-mediated mutations to
contribute to HIV-1 evolution, we used our in silico model
(Figure 1) to simulate stochastic accumulation of G-to-A mutations
in the genome before an obviously lethal mutation (introduction of
a stop codon or loss of an initiation codon) appeared in any gene
(Figure 2B and C). The simulation took into account both the dual
hA3G mutation gradients (PBS-cPPT and cPPT-39PPT) and the
target probability at each G-nucleotide calculated from the
surrounding sequence context. A collection of 4000 HIV-1
sequences – with nonsynonymous (NS, Figure 2B) and synony-
mous (S, Figure 2C) mutations accumulated until one lethal
mutation was introduced – was analyzed. Most of the simulated
mutations displayed the expected dual gradient (black circles).
Very infrequent mutations at the bottom of the graphs result from
contexts that are at or very close to the probability cutoff. To
ensure that this pattern did not reflect a nonuniform distribution of
high probability hA3G targets, we also plotted the distribution of
context probability scores for all G-residues. As can be seen
(Figure 2B and C, gray squares), there is no indication of an
uneven distribution of context probabilities across the HIV-1
provirus.
The distribution of the number of accumulated G-to-A changes
per provirus resulting from our simulations is presented in Figure 3.
For comparison, simulations were also repeated in which all G-
nucleotide sites were considered for successful mutations and
compared to those derived using the 80% probability cutoff
(Figure 2 and above). As expected from our model, without
selection pressure on the virus sequence, NS (red) to S (blue)
mutation ratios were consistent (approximately 3:1) independent of
the number of mutations that were introduced into the viruses.
Further, the numbers of random G-to-A mutations introduced
before a stop codon appeared averaged about 1.6 S and 4.0 NS
mutations, but some individual genomes accumulated as many as
40 substitutions when an 80% hA3G target probability cutoff was
used (Figure 3). This value increased to 72 when all G-nucleotides
were considered. Thus, when all sites were used in simulations,
mutations were more widespread and high scoring hA3G target
contexts accumulated slightly fewer mutations than in simulations
where a probability cutoff was used (Figure S2). This pattern
reflects the fact that higher scoring sites have a larger proportion of
potential stop codons resulting from G-to-A mutations. Together,
these simulation results suggest that a moderate level of G-to-A
mutations is tolerable in the virus sequence during its evolution
without causing significant harm (i.e. premature stops), although
the significance of other NS mutations was not assessed in our
simplified in silico model.
G-to-A mutation footprints in retrovirus evolution
Given the number of G-to-A mutations that could be
introduced in our in silico model, it is conceivable that a low-
level of hA3G-mediated mutations has been introduced into the
HIV-1 sequence during its recent history and that these mutations
might still be distinguishable from the more random RT-induced
G-to-A mutations.
To investigate this possibility, we used our in silico model
(Figure 2A) to calculate the likelihood of each G-nucleotide
context fit to be a hA3G target as outlined in Figure 4A. Briefly,
we summarized the likelihood scores for each G-nucleotide
context and tested for mutation type when changed into an A-
nucleotide. We then calculated a ratio of NS to S sites (Figure 4A).
In the same way, we summarized likelihood scores for currently
residing A-nucleotides, which we treated as putative ancestral G-
nucleotides. Evolutionary theory predicts that the least costly
mutations will have a higher chance to become fixed in the viral
sequence and that deleterious mutations, i.e. mostly NS, will
naturally be sorted out from the virus population due to purifying
selection pressure. Conversely, among target sequences in which
the target G-nucleotide has been changed to an A (referred to here
as ‘‘putative’’ targets), the NS/S ratio should increase with time.
Thus, the action of A3 on ancestral virus should have left a
footprint on the viral genome in the form of an increased NS/S
ratio at A3G targets relative to putative ancestral targets
(Figure 4A). In search of such a footprint, we tested a modern
HIV-1, subtype B sequence for the score and likelihood ratios at
potential hA3G target sites and found an increased NS/S ratio
(p=0.07, x
2 test) when compared to the cognate ratios at putative
ancestral sites (Figure 4B). Indeed, analyses using the group M
consensus sequence reconstructed from subgroup gene consensus
sequences (HIVcon), which most likely has eliminated some
background variation, supported our finding with a higher level of
significance (p=0.04). Increasing the target score cutoff led to
slightly higher ratios for HIV-1, whereas a decreased cutoff had
A3G, HIV-1 Evolution and Drug Resistance
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that differences in NS/S ratios between currently observed G-
nucleotides and putative ancestral hA3G mutation site contexts
were not artifacts from random HIV-1 RT errors, we repeated our
analyses by random sampling of codons from the virus sequences
while not considering context scores or likelihoods. In these
controls we found no significant differences in nonsynonymous to
synonymous ratios between the current and putative ancestral G-
nucleotides (Figure 4B). Thus, we propose that hA3G-induced
mutation has had a significant influence on the HIV-1 genome in
its evolutionary past.
Potential HIV-1 drug resistance from hA3G-mediated G-
to-A mutations
Our analysis implies that, over its evolutionary history, HIV-1
has been subjected to sublethal G-to-A mutations, which have not
had sufficient effect to stop virus proliferation and transmission. An
imperfectly functioning Vif protein might explain this result. Vif
has become an interesting target for new anti-viral drugs [19–21]
since inhibition of its activity could increase the chance for hA3G
to more efficiently restrict virus spread. However, suboptimal
blocking of Vif might also lead to an increase in sublethal hA3G-
induced G-to-A mutations, and potentially more rapid appearance
of drug resistance. To test this possibility, we analyzed the G-
nucleotide contexts in the major HIV-1 genes gag, pro, pol and env
(Figure S2). We hypothesized that combinations of HIV-1
inhibitory drugs, including a potential Vif-targeting drug, could
lead to an increased selection pressure for HIV-1, which might
then benefit from low-level hA3G-mediated G-to-A mutations,
allowing it to escape other drugs like protease-, RT-, integrase-
and fusion-inhibitors.
To test this possibility, we screened a total of about 52,000
mutations resulting from our in silico simulations using either 80%
probability cutoffs or all G-nucleotide context probabilities
(Figure 3), our analyses showed a total of 695 mutations
introduced at known drug resistance sites (Figure 5 and Figure
S2). However, in no case was the frequency of mutations at sites
with high probability scores greatly different from the probability
for all G-to-A mutations regardless of score. Thus, it seems
Figure 2. Human APOBEC3G target context probabilities and
simulation results in HIV-1. (A) The distribution of scores for 10
6
random sequence contexts derived from observed nucleotide frequen-
cies in HIV-1 extending 3 bases upstream and 5 bases downstream of
the target base is shown by the black circles. The black diamonds show
the cumulative frequency distribution, and a boxplot representing this
distribution (median, flanked by boxes indicating first and third
quartiles and whiskers for high and low values) is also shown in black.
The distribution of corresponding context scores for previously
observed sites of hA3G-mediated G-to-A mutations in HIV-1 [9,14] is
shown by the red boxplot. (B, C) Frequency of accumulated
nonsynonymous (B) and synonymous mutations (C) at contexts with
.80% probability derived from 4000 independent simulations of virus
evolution (see Figure 1) are shown (in black) relative to the HIV-1
provirus. The simulated mutations show the expected dual mutation
gradients [10], PBS-cPPT, and cPPT-39PPT. The differences in slope
between 59- and 39-gradients reflect the different gradient lengths
along the virus sequence. Grey symbols show the distribution of all
potential G-to-A mutation sites as a function of their relative
probabilities derived from PSSM scores, thus verifying that the
distributions observed are not due to a nonuniform distribution of
high probability hA3G targets.
doi:10.1371/journal.ppat.1000367.g002
Figure 3. Simulation of hA3G-mediated HIV-1 evolution. A total
of 4000 in silico G-to-A mutated HIV-1 sequences is indicated by grey
crosses plotted as the number of genomes vs. number of mutations per
genome. Bars show nonsynonymous (red) and synonymous (blue)
mutations. Boxplots below show the distributions of viruses with hA3G-
induced mutations, with the median value flanked by boxes indicating
the quartiles and whiskers indicating the highest and lowest number of
mutations in the distributions. Solid boxplots show distributions from
simulations using 80% probability cutoffs for mutations and dashed
boxplots show equivalent results considering all context probabilities.
Complementing boxplots on the right show distributions of accumu-
lated mutations from the simulations using hA3G.
doi:10.1371/journal.ppat.1000367.g003
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side effect of an increased, but still low-level, hA3G-induced
mutation rate resulting from using Vif as an anti HIV-1 drug
target. However, caution is indicated where, due to an altered
selection pressure from anti-viral regimens used in combination,
multiple G-to-A mutations in adjoining contexts could potentially
lead to new drug resistance (Figure S2).
Experimental evaluation of the model
Our current in silico model is based on previously published
experimental data [9,10,14]. To test the role of hA3G more
directly, we performed in vitro passaging experiments on CEM cells
using a previously described HIV-1 vif mutant [18] that was
previously shown to have lost the ability to inhibit hA3G, but
could still inhibit hA3F; therefore G-to-A mutations were
considered to result from either RT-induced errors or hA3G-
mediated changes [17,18]. Western blotting analysis indicated that
the T cell line used did not express detectable levels of hA3F (data
not shown), further supporting the view that hA3F did not
significantly contribute to the pool of G-to-A mutations analyzed.
We also analyzed another vif mutant which is unable to block the
activity of hA3F but can block the activity of hA3G (DRMR.A4).
This mutant replicated with kinetics that were indistinguishable
from those of the wild type virus (unpublished observations). Thus,
we are confident that these cells express little or no hA3F. To
assess the distribution of accumulated mutations, we passaged the
virus sequentially for three rounds over three months, and then
sequenced the vif region (corresponding to positions 5041–5770 of
pNL4-3), amounting to about 166,000 nucleotides from 227
separate genomes. We identified a total of 585 G-to-A mutations
and calculated scores and probabilities for their respective hA3G
mutation site contexts. In the raw sequence data [17,18], we noted
that approximately 87% of the mutations were in GG dinucleotide
contexts, agreeing with frequencies observed by us and others for
vif-defective viruses produced from cells that exclusively express
hA3G (transfected 293T cells).
To evaluate our in silico model predictions we simulated the
same number of mutations observed in vitro into the same pNL4-3
sequence. A comparison of the observed and predicted frequencies
of G-to-A mutations as a function of context probability is shown
in Figure 6A, and the corresponding cumulative distributions are
shown in Figure 6B. We could not detect any significant
differences in the mean values (P=0.41, x
2 test, 30 degrees of
freedom) between our in silico predictions and observations from in
vitro experiments. The larger variation observed in vitro (red
confidence intervals and red outliers) compared to the in silico
results (blue confidence intervals) indicates that other factors such
as nucleic acid structure might also influence the efficiency of
hA3G-mediated mutation. However, given the similarity of the
cumulative distribution, this contribution is likely to be small
compared to the primary sequence likelihood used in our
predictions, implying that our model is capable of accurately
capturing hA3G-mediated mutagenesis during HIV replication.
Discussion
Human A3F and A3G are potent antiviral factors whose
activities, if not blocked by Vif, are capable of causing high levels
of G-to-A mutations in newly made viral DNA. However, their
role in the genesis of naturally occurring mutations is unclear. In
this report, we have built an in silico model to simulate G-to-A
mutations and to analyze their potential role in HIV-1 evolution
and drug resistance. We have found that hA3G activity acting on
prior generations of virus has left detectable footprints in the HIV-
1 genome. Although there are at least ten human APOBEC
members (reviewed in [2,12,22]), including at least one more
potential HIV-1 restriction factor, hA3H [23,24]; we have chosen
to focus on the effects of hA3G on HIV-1 to limit our predictions
and simplify our model in order to reach realistic conclusions. We
also elected to include a wider mutation site context than the more
commonly used GG-dinucleotide, consistent with our previous
studies of nonrandom mA3 targets in endogenous nonecotropic
Figure 4. G-to-A mutation footprints formed during the HIV-1 evolutionary past. (A) The principle of this analysis. Briefly, scores were
summarized for contexts surrounding G-nucleotides and A-nucleotides (treated as putative ancestral G) and analyzed for nonsynonymous (NS) or
synonymous (S) change if mutated G-to-A. For comparison, NS/S ratios were also calculated for random codons derived from nucleotide frequencies
at codon positions found in the provirus ORFs. (B) The NS/S ratio differences in a modern HIV-1 subtype B sequence (AF033819) are shown in the left
panel and HIVcon (group M consensus sequence derived from the individual subgroup consensus sequences) are in the right panel. The NS/S ratio of
hA3G targets (blue) are compared to corresponding putative ancestral targets (red) with an A-nucleotide at the target site as well as to expected
ratios derived from G- and A-nucleotide frequencies and positions in randomly selected codons. P-values from the x
2 distribution (1 degree of
freedom) are shown above the bars.
doi:10.1371/journal.ppat.1000367.g004
A3G, HIV-1 Evolution and Drug Resistance
PLoS Pathogens | www.plospathogens.org 6 April 2009 | Volume 5 | Issue 4 | e1000367MLV [11], to distinguish hA3G-induced G-to-A changes from
randomly introduced HIV-1 RT errors.
G-to-A hypermutation in HIV-1 is clearly capable of limiting
virus proliferation due to the introduction of both missense and
nonsense mutations, which can be directly lethal to the virus [7,8].
The origin of G-to-A changes and their contribution to the bias
and A-richness of the HIV-1 genome have been studied, as has the
role of hA3G as a potential driver of HIV-1 evolution, although
mutations introduced by RT are likely to be of greater general
importance in the evolution of drug-resistant variants [25]. The
hypothesis that hA3G has played an important role in HIV-1
evolution was also discussed in another recent study of HIV-1
nucleotide and codon usage bias [26].
To address the potential role of hA3G-mediated G-to-A
mutations, as distinguished from random HIV-1 RT-introduced
errors, in HIV-1 evolution, we analyzed individual mutation sites
in hA3G target contexts, calculated from independent experimen-
tal data. To minimize bias due to purifying selection, the impaired
vif gene was chosen for analysis of G-to-A mutation frequency.
Another practical reason was that we needed to verify with each
sequence that the Vif inactivating mutation was not reverted to
regain Vif function. Thus, analyzing sequences from the Vif/Vpr
region allowed us to verify the Vif-deficient phenotype. When the
results obtained from this in silico analysis were compared with the
accumulation of G-to-A mutations in vif(-) HIV-1, passaged
repeatedly in CEM cells, we saw no significant difference in mean
number of mutations as a function of their context score, although
the variance of this value was much greater in the latter analysis,
perhaps reflecting effects of secondary structure or some other
feature on the A3G mediated mutation frequency. It should be
emphasized that, although we used the same total number of
mutations observed in vitro for our simulation, the in silico model
was otherwise completely independent of the in vitro study, yet the
two did not give significantly different results. Thus, the similarity
between experiment and simulation supports the accuracy of our
model, as well as its suitability for estimating mutational events.
Further support for our hA3G footprint observations in HIV-1
and our estimates of moderately high tolerance of G-to-A changes
before introduction of deleterious stop mutations in our simula-
tions could also be observed in a recent study of genetic variation
in early founder HIV-1 virus populations from primary infections
[27].
Our results imply that although hA3G-mediated G-to-A
mutations likely have had a detectable effect on HIV-1 evolution
that is traceable through mutational footprints Indeed, several
studies of endogenous retroviruses from different genera and host
species have recently shown evolutionary effects caused by A3-
introduced G-to-A mutations, some of which likely contributed to
provirus inactivation [11,28,29]. However, it is likely that other
mutagens, including other A3 proteins, as well as HIV-1 RT are
also important contributors to the nucleotide bias in the virus
genome [25,26].
The HIV-1 Vif protein has drawn interest as a drug target since
interfering with its action could theoretically allow hA3G to escape
degradation and thus restrict virus proliferation [2,19,21].
However, an increased rate of G-to-A mutations compared to
that from the error prone RT enzyme, as a result of an incomplete
block of Vif, could potentially be used by HIV-1 to accelerate
evolution of drug resistance and immune escape [30]. Variation at
G-nucleotide sites is not uncommon within a HIV-1 population
and polymorphism at HIV-1 drug resistance sites has been
observed in single genome sequencing studies [31,32]. Here, we
used our model to estimate the chance for HIV-1 to benefit from
such increased genetic variation due to hA3G-introduced
mutations. G-to-A-induced drug resistance has been described,
but until now its discussion has focused on GG-dinucleotide
contexts [30,33]. Our in silico model instead uses the extended
information of the sequence context surrounding the mutation site
and enabled us to calculate a probability score for each possible
site. This approach enabled us to screen the entire HIV-1 genome
and estimate the likelihood of mutations in the context of the dual
gradients arising during reverse transcription [9,10]. The moder-
ate number of hA3G-mediated G-to-A mutations at known drug
resistance sites implies that the hA3G-Vif interaction can be a
potential target for new antiviral drugs, with little or no concern
for enhancement or appearance of resistance to other antiviral
Figure 5. Drug resistance mutations potentially caused by G-to-A mutations. Codons for known mutation sites are concatenated from full
mutation site contexts in the HIV-1 gag, pol and env sequences (Figure S2). Lower panel: black bars indicate calculated probabilities at G-to-A
mutation positions (derived from Figure 2A). The upper panel shows stacked bars for accumulated mutations at each position from simulations using
the 80% probability cutoff (nonsynonymous red or synonymous blue) or all probabilities (orange or light blue). Abbreviations: PI, protease inhibitors;
NRTI, nucleoside RT inhibitors; NNRTI, non-nucleoside RT inhibitors; INI, integrase inhibitors; FI, fusion inhibitors.
doi:10.1371/journal.ppat.1000367.g005
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not seem overly problematic for the evolution of drug resistance in
HIV-1. However, as pointed out by Mulder et al, [34] it cannot be
entirely excluded that other A3-induced changes in high scoring
hA3G target sites in the vicinity of current drug targets (Figure S2)
not associated with drug resistance to date, might give rise to
compensatory or even new resistance mutations. In that study, the
authors describe a mutation, M184I in RT, which emerged in a
partially impaired HIV-1 vif mutant. The conclusion that hA3G
was causing this mutation was based on the dinucleotide context
and the results are somewhat contradictory to our findings
(Figure 5). Given that G-to-A mutations are the most common RT
errors and our previous experience and support from larger
mutation site contexts derived from the literature, we emphasize
that such a short dinucleotide context is unlikely to be sufficient to
readily distinguish bona fide hA3G induced G-to-A mutations from
RT error.
In conclusion, we have found evidence that low levels of
APOBEC3G-induced mutagenesis have affected HIV-1 evolution,
leading to enhanced rates of variation at sites with a high
probability of match to the optimum context for hA3G-mediated
deamination. The low levels of G-to-A mutation could allow the
viruses to achieve enhanced genetic variation. However, since the
predicted effect on resistance to standard antiviral drugs is likely to
be small, we propose that concerns over increased resistance
mutations should not impede development of HIV-1 Vif as a
candidate drug target.
Supporting Information
Figure S1 Position-specific scoring matrix (PSSM) derived from
observed G-to-A mutation site contexts found in the literature.
Found at: doi:10.1371/journal.ppat.1000367.s001 (0.06 MB PDF)
Figure S2 HIV-1 (AF033819) gag, pol and env polyprotein ORFs
and amino acid translations. Lower panel black bars indicate
calculated hA3G context probabilities for each. Upper panels
show stacked bars for accumulated number of simulated
mutations. Red bars indicate nonsynonymous (i.e. change in
amino acid) mutations and blue bars indicate synonymous
mutations. Dark shaded bars (red and blue) represent simulations
using an 80% probability cutoff for mutations and lighter shaded
bars (orange and light blue) represent simulations using all context
probabilities. Known resistance mutations are shown as shaded
codons and amino acids. Grey shading represents amino acid
changes due to mutations other than G-to-A editing which are
shaded in red.
Found at: doi:10.1371/journal.ppat.1000367.s002 (0.30 MB PDF)
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